Abstract
Mortalin is a member of Hsp70 family of stress chaperones. It was first identified as a protein involved in the senescence of mouse cells. Genetic studies revealed that there are two mouse mortalin alleles coding for two proteins (mot-1 and mot-2) that differ in only two amino acids in the carboxy-terminus, but have contrasting activities. Whereas mot-1 accelerated senescence, mot-2 extended the lifespan of mouse cells in culture. In human cells, only one kind of mortalin protein has been identified so far and is shown to be functionally equivalent to mouse mot-2. Whereas mortalin is enriched in cancer cells and contributes to carcinogenesis, the old age brain disorders show its deficiency. As we demystify its deux de machina, accumulating evidence reveal that mortalin may be “druggable” bidirectionally to either treat cancer or neuro-degenerative disorders.
Keywords: Mortalin, chaperone, cancer, aging, target, therapy, Hsp70, alleles, senescence, neuro-degenerative disorders.
Current Pharmaceutical Design
Title:Druggability of Mortalin for Cancer and Neuro-Degenerative Disorders
Volume: 19 Issue: 3
Author(s): Custer C. Deocaris, Wen-Jing Lu, Sunil C. Kaul and Renu Wadhwa
Affiliation:
Keywords: Mortalin, chaperone, cancer, aging, target, therapy, Hsp70, alleles, senescence, neuro-degenerative disorders.
Abstract: Mortalin is a member of Hsp70 family of stress chaperones. It was first identified as a protein involved in the senescence of mouse cells. Genetic studies revealed that there are two mouse mortalin alleles coding for two proteins (mot-1 and mot-2) that differ in only two amino acids in the carboxy-terminus, but have contrasting activities. Whereas mot-1 accelerated senescence, mot-2 extended the lifespan of mouse cells in culture. In human cells, only one kind of mortalin protein has been identified so far and is shown to be functionally equivalent to mouse mot-2. Whereas mortalin is enriched in cancer cells and contributes to carcinogenesis, the old age brain disorders show its deficiency. As we demystify its deux de machina, accumulating evidence reveal that mortalin may be “druggable” bidirectionally to either treat cancer or neuro-degenerative disorders.
Export Options
About this article
Cite this article as:
C. Deocaris Custer, Lu Wen-Jing, C. Kaul Sunil and Wadhwa Renu, Druggability of Mortalin for Cancer and Neuro-Degenerative Disorders, Current Pharmaceutical Design 2013; 19 (3) . https://dx.doi.org/10.2174/1381612811306030418
DOI https://dx.doi.org/10.2174/1381612811306030418 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mammaglobin-Based Strategies for Treatment of Breast Cancer
Current Cancer Drug Targets FADS1 is a Prognostic Biomarker in Bladder Cancer: A Study Based on TCGA Data
Combinatorial Chemistry & High Throughput Screening Anti-Invasive and Anti-Metastasis Strategies: New Roads, New Tools and New Hopes
Current Cancer Drug Targets 1,3,5-Triazine Analogs: A Potent Anticancer Scaffold
Current Signal Transduction Therapy Computational Methods and Algorithms for Mass Spectrometry Based Differential Proteomics: Recent Advances, Perspectives and Open Problems
Current Proteomics LncRNA as a Therapeutic Target for Angiogenesis
Current Topics in Medicinal Chemistry Arsenic Immunotoxicity and Immunomodulation by Phytochemicals: Potential Relations to Develop Chemopreventive Approaches
Recent Patents on Inflammation & Allergy Drug Discovery Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors
Current Gene Therapy A Role for Milk Proteins and their Peptides in Cancer Prevention
Current Pharmaceutical Design Sleep Related Disorders in the Elderly: An Overview
Current Respiratory Medicine Reviews CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Current Pharmaceutical Biotechnology Self-Assembling Peptides: Potential Role in Tumor Targeting
Current Pharmaceutical Biotechnology The Effect of Sex and Gender on Diabetic Complications
Current Diabetes Reviews Immunosensors in Early Cancer Diagnostics: From Individual to Multiple Biomarker Assays
Current Medicinal Chemistry Small Heat Shock Proteins and the Endoplasmic Reticulum: Potential Attractive Therapeutic Targets?
Current Molecular Medicine Applications of HPLC-MALDI-TOF MS/MS Phosphoproteomic Analysis in Oncological Clinical Diagnostics
Current Proteomics Advances in Hyaluronic Acid-Based Drug Delivery Systems
Current Drug Targets Is there U-turn from Insulin Back to Pills in Diabetes?
Current Vascular Pharmacology Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Recent Progress in the Development of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents